Q3 EPS Estimates for Stevanato Group Decreased by Analyst

Stevanato Group S.p.A. (NYSE:STVN) – Research analysts at William Blair cut their Q3 2025 EPS estimates for shares of Stevanato Group in a note issued to investors on Tuesday, November 5th. William Blair analyst M. Larew now forecasts that the company will post earnings of $0.16 per share for the quarter, down from their previous forecast of $0.17. The consensus estimate for Stevanato Group’s current full-year earnings is $0.50 per share. William Blair also issued estimates for Stevanato Group’s Q4 2025 earnings at $0.23 EPS and FY2025 earnings at $0.63 EPS.

Stevanato Group (NYSE:STVN) last issued its earnings results on Tuesday, November 5th. The company reported €0.12 ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.13 ($0.14) by (€0.01) (($0.01)). Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. The firm had revenue of €277.90 million for the quarter, compared to analysts’ expectations of €274.36 million. During the same quarter in the previous year, the firm posted $0.16 EPS. The firm’s revenue for the quarter was up 2.4% compared to the same quarter last year.

Other analysts have also recently issued reports about the stock. Morgan Stanley decreased their price target on shares of Stevanato Group from $26.00 to $22.00 and set an “equal weight” rating for the company in a research report on Monday, July 15th. Citigroup decreased their target price on Stevanato Group from $30.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, August 7th.

Stevanato Group Price Performance

Stevanato Group stock opened at €21.78 ($23.93) on Thursday. The firm has a fifty day moving average of €19.68 and a 200-day moving average of €20.30. Stevanato Group has a 52-week low of €16.56 ($18.20) and a 52-week high of €34.73 ($38.16). The company has a quick ratio of 1.13, a current ratio of 1.81 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $6.44 billion, a P/E ratio of 46.34, a PEG ratio of 10.18 and a beta of 0.58.

Institutional Investors Weigh In On Stevanato Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hilltop National Bank grew its stake in shares of Stevanato Group by 34.3% during the second quarter. Hilltop National Bank now owns 4,395 shares of the company’s stock valued at $81,000 after acquiring an additional 1,122 shares in the last quarter. Lindenwold Advisors INC boosted its holdings in Stevanato Group by 13.5% in the third quarter. Lindenwold Advisors INC now owns 11,930 shares of the company’s stock valued at $239,000 after purchasing an additional 1,415 shares during the last quarter. Raymond James Trust N.A. boosted its holdings in Stevanato Group by 18.7% in the second quarter. Raymond James Trust N.A. now owns 10,239 shares of the company’s stock valued at $188,000 after purchasing an additional 1,613 shares during the last quarter. First Bank & Trust grew its stake in Stevanato Group by 29.1% during the 3rd quarter. First Bank & Trust now owns 14,109 shares of the company’s stock valued at $282,000 after purchasing an additional 3,182 shares in the last quarter. Finally, Trust Point Inc. increased its holdings in Stevanato Group by 16.0% during the 3rd quarter. Trust Point Inc. now owns 23,336 shares of the company’s stock worth $467,000 after purchasing an additional 3,222 shares during the last quarter.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.